• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

More Respimat data from Boehringer

September 8, 2016 By Sarah Faulkner

Boehringer Ingelheim RespimatBoehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo.

The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London.

This comes 1 day after results from another clinical trial showed the company’s drug-device Stiolto Respimat aids patients with chronic obstructive pulmonary disease walk for longer periods of time without experiencing shortness breath.

The CanoTinA trial looked to investigate the use of tiotropium, a drug that helps to keep the airways to the lung open, with Respimat in kids that are already taking an inhaled corticosteroid. Respimat is not approved in the US for children under 12.

“Asthma is the most common chronic childhood disease, but many children still continue to experience asthma symptoms despite taking other maintenance therapies,” Dr. Christian Vogelberg of Germany’s University Children’s Hospital Dresden said in a press release. “These new results showed significant lung function improvements for children with asthma and importantly confirm that the safety profile of tiotropium Respimat in children aged six years and above is comparable to placebo.”

Study researchers found that the safety and tolerability of the drug is comparable to the placebo, while significantly improving lung function.

Four other studies organized by Boehringer Ingelheim also show that adding tiotropium Respimat is just as safe as adding a placebo in kids ages 6-17. This clinical trial is one of 18 clinical studies from the Phase II and Phase III UniTinA-asthma clinical development program. Over 6,000 patients participated, including 1,800 children ages 1-17.

“At Boehringer Ingelheim, we have a strong commitment to scientific research with the goal of improving the care of people living with serious respiratory diseases such as asthma,” said Dr. William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim, in prepared remarks. “Data from these studies build on the body of evidence that we have learned about tiotropium Respimat as an add-on therapy for asthma.”

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Boehringer Ingelheim Pharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS